| 8.23 0.37 (4.71%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.88  |
1-year : | 11.54 |
| Resists | First : | 8.46 |
Second : | 9.88 |
| Pivot price | 6.61 |
|||
| Supports | First : | 6.63 |
Second : | 5.5 |
| MAs | MA(5) : | 7.65 |
MA(20) : | 6.42 |
| MA(100) : | 7.41 |
MA(250) : | 9.61 |
|
| MACD | MACD : | 0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 90.6 |
D(3) : | 89.3 |
| RSI | RSI(14): 71.3 |
|||
| 52-week | High : | 24.17 | Low : | 5.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ARCT ] has closed below upper band by 3.0%. Bollinger Bands are 101.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.47 - 8.5 | 8.5 - 8.52 |
| Low: | 7.66 - 7.69 | 7.69 - 7.72 |
| Close: | 8.17 - 8.22 | 8.22 - 8.27 |
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
Fri, 14 Aug 2026
Dimensional Fund Advisors LP Decreases Holdings in Arcturus Therapeutics Holdings Inc. $ARCT - marketbeat.com
Thu, 13 Aug 2026
HC Wainwright Has Optimistic Outlook of ARCT Q3 Earnings - marketbeat.com
Tue, 11 Aug 2026
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline - TradingView
Tue, 11 Aug 2026
ARCT: Advancing mRNA therapies for CF and OTC with phase III plans, strong funding, and key partnerships - TradingView
Sat, 08 Aug 2026
Arcturus Therapeutics (ARCT) Stock Jumps As Cash Runway Reframes Pipeline Risk - simplywall.st
Fri, 07 Aug 2026
Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 2.615e+007 (%) |
| Held by Institutions | 7.9 (%) |
| Shares Short | 6,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.548e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -143.9 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 403.7 % |
| Return on Equity (ttm) | -19.2 % |
| Qtrly Rev. Growth | 5.471e+007 % |
| Gross Profit (p.s.) | -40.97 |
| Sales Per Share | -16.31 |
| EBITDA (p.s.) | -1.94449e+007 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -59 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.51 |
| Price to Cash Flow | 2.48 |
| Dividend | 0 |
| Forward Dividend | 7e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|